Collaboration and License Agreement (Tables)

3 Months Ended

Mar. 31, 2018

Collaboration And License Agreement Disclosure [Abstract]

Changes in Contract Assets and Liabilities

The following table presents changes in the Company’s contract assets and liabilities, which excludes research and development reimbursements under the mavacamten registration program plan, for the three months ended March 31, 2017 and 2018 (in thousands):

	Three Months Ended March 31, 2018
	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Contract liabilities:
Deferred revenue	$	33,558	$	—	$	(5,331	)	$	28,227

	Three Months Ended March 31, 2017
	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Contract assets:
Receivable from collaboration partner	$	45,000	$	—	$	(45,000	)	$	—
Contract liabilities:
Deferred revenue	$	45,000	$	—	$	(2,410	)	$	42,590

Schedule of Receivables and Prepayments From Collaboration Partner

The following table presents the RPP related receivables and prepayments (in thousands):

	Balance at December 31, 2017		Payments Received from Sanofi under RPP		ActualExpenses Incurred During the Quarter			Balance at March 31, 2018
Receivable from collaboration partner	$	1,013	$	1,013	$	—		$	—
Prepayment from collaboration partner	$	4,432	$	6,090	$	(2,821	)	$	7,701